… with significantly lower odds of amyotrophic lateral sclerosis both in European and East …
therapeutic promise and accelerates translates this finding into desperately needed treatments …

… Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting motor neurons
… ]) limit therapeutic options. The only USA Food and Drug Administration approved drugs for …

… The earliest description of amyotrophic lateral sclerosis (ALS) dates back more than 140
years ago. In 1869, a French neurologist Jean-Martin Charcot described the selective …

… Amyotrophic lateral sclerosis (ALS) is a fatal and fast progressive motoneuron degenerative
disorder. There are still no drugs … therapeutical targets for ALS from bench to bed side (45, 46…

… trauma is considered a potential risk factor of amyotrophic lateral sclerosis (ALS), but their
… targeted treatment regimens and make prophylactic strategies for ALS in traumatic patients. …

… drug AmX0035 has beneficial effects on survival and function in people with amyotrophic
lateral sclerosis (… The two drugs individually exhibit neuroprotective properties in experimental …

… effective treatments for those patients suffering from chronic/progressive multiple sclerosis (…
and early attempts to advance such therapies from the bench to the bedside. It is the authors' …

… States Food and Drug Administration (FDA) for treatment of amyotrophic lateral sclerosis (ALS), …
Is the Subject Area "Amyotrophic lateral sclerosis" applicable to this article? Yes No …

… Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease … of research
in the regenerative medicine field. The effectiveness of stem cell therapies may be based on …

… Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by the …
treatment options in the management of each environmental factor previously discussed. …